Lymphoma Clinical Trials

Showing 3321-3340 of 3,379 trials

Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT00290004

The primary purpose of this study is to evaluate the safety, toxicities, dosage and response rate for an investigational drug, motexafin gadolinium, administered to patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. The secondary purpose of this study is to evaluate the clinical benefit rate, the time it takes for a patient's chronic lymphocytic leukemia or small lymphocytic lymphoma to worsen, the duration of response and the time during which patients survive without chronic lymphocytic leukemia or small lymphocytic lymphoma worsening. Additionally, the patient's response to motexafin gadolinium will be compared to the response of the patient's cells in a laboratory to motexafin gadolinium.

Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaLeukemia+1 more

Pharmacyclics LLC.35 participantsStarted Nov 2005

Los Angeles, California, United States • San Diego, California, United States • Chicago, Illinois, United States +1 more locations

COMPLETEDPhase 2

Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL)

NCT00346684

First line therapy for patients with Lymphocyte predominant Hodgkin´s Disease (LPHD) in clinical stage IA using the monoclonal anti-CD20 antibody rituximab

Lymphocyte Predominant Hodgkin´s Lymphoma (LPHD)

University of CologneStarted Jul 2006

Cologne, Germany

UNKNOWNPhase 2

BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma

NCT00039156

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BAY 59-8862 in treating patients who have refractory non-Hodgkin's lymphoma.

Lymphoma

TheradexStarted Jan 2002

Miami Beach, Florida, United States • Chicago, Illinois, United States • Shreveport, Louisiana, United States +12 more locations

Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL)

BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma

Related Searches

Study of Bortezomib (Velcade) in Combination With Dexamethasone to Treat Patients With Relapsed Hodgkin's Lymphoma

Open-Label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of VELCADE in Patients With Either Advanced Solid Tumors or Non-Hodgkin's Lymphoma.

Treatment of Burkitt Lymphoma/Leukemia and B Large Cell NHL

11C-Acetate PET/CT Non-FDG-Avid Tumors

Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma

A Study of Peripheral Blood Progenitor Cell (PBPC) Mobilisation by Chemotherapy With Pegfilgrastim or Filgrastim in Subjects With Non-Hodgkin's Lymphoma

Large Cell Lymphoma Pilot Study III

Treatment for Patients With Stage III or IV Non-Hodgkin Lymphoma

Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma

Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients

A Phase I Trial of Continuous Infusion UCN-01 in Patients With Refractory Neoplasms

Evaluation and Natural History of Children With Cancer and AIDS

A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833

Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac

HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malignancies

A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma

Phase I Study of Intrathecal Topotecan